Stockwinners Market Radar for February 24, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EST Cathie Wood's ARK Investment bought 31.1K shares of Tesla today

18:26 EST ReNew Energy Global CFO Muthukumaran resigns - On February 24, 2022, the Board of Directors of ReNew Energy Global plc accepted the resignation of D.Muthukumaran as the Chief Financial Officer of ReNew. Muthukumaran will continue as ReNew's Chief Financial Officer until the effective date of his resignation on or around the end of Fiscal Year ended March 31, 2022. Muthukumaran is resigning to pursue other interests and his decision to resign was not as a result of any disagreements with ReNew on any matter. The Board thanks Muthukumaran for his services and wishes him well in his new endeavors. Following Muthukumaran's resignation, Mr. Kailash Vaswani will be appointed as an interim Chief Financial Officer of ReNew until the Board appoints a new Chief Financial Officer.

17:44 EST General Dynamics awarded $108.15M Navy contract modification - General Dynamics was awarded a $108.15M cost-plus-fixed-fee and cost-plus-incentive-fee modification to previously awarded contract for Smart Start maintenance, repair, and modernization efforts in support of the USS Hartford engineered overhaul. Work will be obligated at the time of award, and funds in the amount of $47.16M will expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:40 EST Beyond Meat says expect 'flat to modest' Q1 revenue growth - CFO Philip Hardin says: "We expect flat to modest net revenue growth in Q1, accelerating through the year, primarily due to newly secured distribution expansion in the U.S. retail, new product launches acceleration in international markets as a result of EU price resets and extended shelf life driving incremental distribution as well as growth in China; anticipated limited-time offerings at QSR customers and as we lap easier comparison periods in the back half of the year. Although we are not providing full year margin guidance at this time, we did want to provide some additional context for our Q1 2022 margins. We expect gross margin in the first quarter to fall well below more normalized levels again, driven by the aforementioned short-term higher manufacturing and logistics costs that are in existing inventory, with added pressure from a new product that we'll launch in the coming weeks."

17:36 EST Talos Energy sees FY22 average daily production 60-64 MBoe/d - Sees FY22 CapEx $450M-$480M.

17:34 EST View Inc. names Toby Cosgrove chairman, Amy Reeves CFO - View Inc. announced multiple leadership appointments. Amy Reeves has been promoted to Chief Financial Officer and Bill Krause to Chief Legal Officer, effective immediately. Ms. Reeves and Mr. Krause will report to View's CEO, Dr. Rao Mulpuri. In addition, Board Director Dr. Toby Cosgrove has been appointed Chairman. "Everyone at View has been impressed with how Amy and Bill have stepped up to address our recent challenges, while driving strong business growth," said Mulpuri. "They demonstrated deep domain expertise, sharp business acumen, proven operational proficiency, and unwavering commitment to View's mission. We could not be more excited to have them take on larger roles within the company." The Board also named Dr. Toby Cosgrove Chairman. Dr. Cosgrove, former CEO of the Cleveland Clinic and a world-renowned expert in the healthcare industry, has served on View's Board since March 2021. Dr. Cosgrove holds 30 patents and currently serves as Executive Advisor to the Cleveland Clinic, advising executive leadership on strategies for national and international growth.

17:33 EST LivaNova says first patient implanted in OSPREY study of aura6000 - LivaNova "announced the first patient implanted in the investigational device exemption clinical study, "Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation". The randomized controlled trial seeks to demonstrate the safety and effectiveness of the LivaNova aura6000(TM) System, an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea. The first OSPREY patient was implanted by Dr. Mitchell Miller at BayCare's Morton Plant Hospital in Clearwater, Florida."

17:31 EST Granite announces three contracts totaling $23.8M - Granite announced the award of three contracts totaling approximately $23.8M by Ellis-Prairie Soil and Water Conservation District. Located in Ellis County, Texas, the first contract was included in Granite's fourth quarter 2021 CAP and the remaining two contracts are anticipated to be included in Granite's first quarter 2022 CAP. Granite's scope of work includes the rehabilitation and upgrading of floodwater retarding structures at three sites. In total, these three projects include 178,000 CY of excavation, 51,000 CY of embankment, installation of principal spillway inlets, three labyrinth weir structures and accompanying 18" x 18" slide gates, associated pipework, irrigation, pollution control, and removal of water. The upgrades at each site will be integral in supporting the ongoing operations of the district's series of structures and dams, which are located throughout the county to help protect downstream areas from flooding after rain events and temporarily control rainfall runoff.

17:23 EST Jasper Therapeutics' JSP191 in MDS or AML to feature in presentation - Jasper Therapeutics announced that the preliminary data from a Phase 1b study of the company's JSP191 first-in-class anti-CD117 monoclonal antibody will be presented as a late breaking abstract at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings, to be held in Salt Lake City, UT, from April 23-26, 2022. The data from 17 patients over the age of 60 with MDS or AML show JSP191, in combination with low dose radiation and fludarabine conditioning, to be well tolerated in an older population with no infusion toxicities observed and no JSP191-related serious adverse events. Furthermore, this regimen achieved engraftment with neutrophil recovery in all 17 of 17 subjects and clearance of MRD in 12 of 15 subjects positive for MRD at screening.

17:20 EST Albemarle raises dividend to 39.5c per share - The Board of Directors of Albemarle Corporation announces that it has declared a quarterly dividend of 39.5c per share. The dividend, which has an annualized rate of $1.58, is payable April 1 , to shareholders of record at the close of business as of March 18. This year marks Albemarle's 28th consecutive year raising its dividend.

17:20 EST Sprouts Farmers Market appoints Nicholas Konat as COO - Sprouts Farmers Market (SFM) announced that Nicholas Konat has been appointed as president and chief operating officer of the company, effective March 21. Konat has most recently served as chief merchandising officer at Petco (WOOF), a leading brand in the U.S. pet care industry and will oversee the company's operations, marketing, merchandising, and innovation functions and report to Jack Sinclair, chief executive officer.

17:16 EST U.S. Silica increases prices on cristobalite products - U.S. Silica said that a portion of its Industrial and Specialty Products business will increase prices for most of its non-contracted whole grain and ground cristobalite products. These products are produced in its Millen, GA, Berkeley Springs, WV and Columbia, SC facilities and used primarily in building products, foundry, plastics, and paints and coatings. Price increases will range up to 25%, depending on the product and grade. The price increases are effective for shipments starting April 1. This increase is driven by ongoing inflationary pressures around raw materials, packaging, logistics and maintenance expenses.

17:15 EST Baudax Bio drops 28% to $3.15 after common stock offering

17:04 EST Americold Realty Trust appoints George Chappelle Jr. as CEO - Americold Realty Trust announced that its Board of Trustees has appointed George F. Chappelle Jr. as Chief Executive Officer, effective immediately. "After a thoughtful search process, the Board unanimously concluded that George is the right executive to lead Americold forward," said Mark Patterson, Chairman of the Americold Board. "George is an exemplary leader with a proven record of execution and a deep understanding of our business and industry. He has hit the ground running since joining as Interim CEO last year, advancing efforts to support customers and position Americold for success. With George now at the helm on a permanent basis, the Board is confident in Americold's ability to drive growth and long-term value creation."

16:58 EST Etsy jumps 16% to $149.08 after Q4 results beat estimates

16:56 EST American Homes 4 Rent reports Q4 same-store NOI up 9.8% y/y - Reports Q4 average occupancy of 97.6%

16:56 EST SM Energy sees 2022 production 51-54 MMBoe - Approximately 51-54 MMBoe or 140-148 MBoe/d at 46-47% oil; assumes ethane processing for the full year. This projection implies low single-digit production growth year-over year. Sees 2022 Capital expenditures $750M, excluding acquisitions.

16:53 EST Home Depot names Paula Santilli and Caryn Seidman-Becker to board - The Home Depot (HD) announced the appointment of Paula Santilli, CEO of PepsiCo (PEP) Latin America, and Caryn Seidman-Becker, chair and CEO of Clear (YOU), to its board of directors, effective March 1. Following the appointment of Santilli and Seidman-Becker, The Home Depot will have 14 directors.

16:47 EST Afya to acquire Alem da Medicina for R$16M - Afya Limited has executed the purchase agreement for the acquisition of 100% of the total share capital of Alem da Medicina, through its wholly-owned subsidiary Afya Participacoes S.A. The consummation is subject to certain customary precedent conditions. Alem da Medicina is a medical content online platform for physicians and medical students that provides educational tools besides technical medical content that can assist them throughout their careers. Its robust content includes mentoring for residency, soft skills, finance, accounting, and investment basics for physicians. The aggregate purchase price is R$16M and will be paid to sellers in cash. An earn-out of up to R$19.2M can be paid related to revenue goals established for 2023 and 2024.

16:45 EST NortonLifeLock receives antitrust clearance in Spain for merger with Avast plc - NortonLifeLock announced its recommended merger with Avast plc received antitrust clearance from Spain's National Markets and Competition Commission. The U.K. Competition and Markets Authority's antitrust review of the merger with Avast plc remains ongoing and is the final regulatory condition to close.

16:42 EST Select Medical announces $1B share repurchase program - The board of directors of Select Medical has authorized a common stock repurchase program to repurchase up to $1B worth of shares of its common stock. The common stock repurchase program will remain in effect until December 31, 2023, unless further extended or earlier terminated by the board of directors

16:39 EST Inogen sees Q1 revenue similar to Q4, sees FY22 revenue up mid-single digits - Inogen states: "The Company continues to see ongoing uncertainty in the business mainly related to supply chain disruptions, in addition to increased cost of critical components, and the continued and varying impacts of the COVID-19 pandemic. As a result, the Company is not providing detailed guidance for 2022, but expects total revenue in the first quarter of 2022 to be similar to the fourth quarter of 2021 and expects 2022 full year-over-year revenue growth to be in the mid-single digit range versus 2021. The Company believes the semiconductor chip shortage experienced across many industries has and will likely continue to have a negative impact on its ability to manufacture products as these chips are used across all its POCs in both its batteries and printed circuit boards. The Company is actively working with its suppliers both in the regular and open market channels to continue to procure necessary semiconductor chips in addition to working on certain product redesign opportunities. The Company expects challenges in terms of supply and pricing inflation until supply meets demand and prices stabilize. If the Company is unable to obtain sufficient supply, it could be forced to further slowdown or temporarily halt production. The Company also expects increased cost of goods sold per unit in the first quarter of 2022 due to cost inflation of materials and labor throughout the supply chain, primarily related to semiconductor chips price increases. The Company expects $4.5M to $5.5M of incrementally higher material costs associated with open-market purchases of semiconductor chips used in its batteries and POCs for the first quarter of 2022, which will vary based on total systems and batteries sold with semiconductor chips bought on the open market."

16:38 EST LeMaitre announces $20M share repurchase authorization - On February 22, the Company's Board of Directors authorized the repurchase of up to $20.0mm of the Company's common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 22, 2023, unless extended by the Board.

16:36 EST Orion Engineered to increase global specialty carbon black prices - Orion Engineered Carbons announced it will raise prices for all specialty carbon black customers. The increase, which will be communicated individually with customers, will vary depending on the product, manufacturing process and location. "Orion faces a sharp increase in raw material, operations and supply chain costs that makes this price adjustment necessary. It will enable us to continue to deliver reliable and sustainable solutions to our customers," said Corning Painter, CEO of Orion. The increased pricing will be effective for all shipments beginning April 1, 2022, or as contracts allow.

16:34 EST Eli Lilly announces FDA approval of Jardiance - The U.S. FDA has approved Jardiance 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, Boehringer Ingelheim and Eli Lilly and Company announced.

16:32 EST Gap raises quarterly dividend 25% to 60c per share - Gap announced its board of directors approved plans to increase the company's annual dividend per share to 60c in fiscal year 2022, a 25% increase from the company's current annualized rate of 48c. The company announced that its board of directors has authorized a first quarter fiscal year 2022 dividend of $0.15 per share, payable on or after April 27, 2022 to shareholders of record at the close of business on April 6, 2022.

16:29 EST Carvana acquires KAR's ADESA's U.S. auction unit for $2.2B in cash - Carvana (CVNA) signed a definitive agreement to acquire ADESA's U.S. physical auction business, a wholly owned subsidiary of KAR Global (KAR), for $2.2B in cash. ADESA U.S. is the second largest provider of wholesale vehicle auction solutions in the United States with 56 sites and approximately 4,500 corporate and operations team members, the company said in a statement. Carvana will continue to operate ADESA U.S.'s existing wholesale auction business and related services under the ADESA brand. ADESA U.S. President John Hammer additional senior and executive leadership and teams will transition to Carvana after the deal is closed. The ADESA U.S. business generated over $800M of revenue and over $100M of EBITDA in 2021. Carvana has received committed financing of up to $3.275B from JPMorgan Chase Bank N.A. and Citi and intends to fund the purchase price and an additional $1B in improvements across the 56 sites through a committed debt financing.

16:26 EST Dell Technologies initiates quarterly dividend of 33c per share - The company announces that its board of directors has approved a dividend policy under which the company intends to pay quarterly cash dividends on its common stock, with an initial dividend rate of $1.32 per share per year for fiscal 2023, or approximately $1B in aggregate. The board has declared the initial quarterly dividend of 33c per share, which will be payable on April 29 to stockholders of record as of April 20.

16:23 EST Southwestern Energy sees Q1 total production 411-426 Bcfe - Sees FY22 total production 1,683-1,723 Bcfe.

16:22 EST Allison Transmission raises quarterly dividend to 21c from 19c per share - Payment will be made on March 18, to stockholders of record at the close of business on March 7.

16:21 EST EOG Resources declares $1.00 per share special dividend - The board of directors of EOG declared a dividend of 75c per share on EOG's common stock. The dividend will be payable April 29 to stockholders of record as of April 15. The indicated annual rate is $3.00 per share. The board of directors also declared a special dividend of $1.00 per share on EOG's common stock. The special dividend will be payable March 29 to stockholders of record as of March 15.

16:19 EST Universal Health authorizes $1.4B increase to stock repurchase plan - On February 24, the Board of Directors authorized a $1.4B increase to the stock repurchase program.

16:17 EST Block sees Square GPV up 35% year-over-year for January and February - Block said for the months of January and February, in aggregate, Square GPV is expected to be up 35% year over year, and the two-year CAGR is expected to be up 16%. "Square GPV growth experienced a slowdown in January, which we believe was due to the effects of the omicron variant, before growth recovered in February," the company said. Block added: "In January and February, we expect Cash App gross profit to grow on a year-over-year and two-year CAGR basis, driven by growth in monthly transacting actives, engagement across our ecosystem, and inflows into Cash App. On January 31, 2022, we completed the acquisition of Afterpay. Afterpay will be included in our first quarter financial results for the months of February and March 2022. We intend on reporting Afterpay's financial results allocated to each of our Square and Cash App ecosystems."

16:12 EST Aerie Pharmaceuticals sees FY Glaucoma franchise net product revenues up 16%-25%

16:09 EST Evertec acquires BBR SpA for $60M - Evertec announced that it entered into a share purchase agreement to acquire 100% of the outstanding shares of BBR SpA, a Santiago, Chile based payment solutions and business technology company with operations in Peru. The aggregate purchase price for the shares is CLP 48,600 million, approximately $60 million at current exchange rates and is subject to customary adjustments. Mac Schuessler, Evertec's President and Chief Executive Officer stated, "The acquisition of BBR complements our existing technology and product portfolio in Chile and opens the Peruvian market for Evertec. With this acquisition, we continue expanding our footprint and solidifying our position as a leading Latin American payment processing company." The transaction is subject to customary closing conditions, including receipt of US federal bank regulatory approval, which is dependent on factors outside the control of Evertec. There is no assurance of when or if such approval will be obtained.

16:08 EST Evertec, Popular modify, extend main commercial agreements - Evertec (EVTC) announced an agreement with Banco Popular de Puerto Rico ("BPPR") and its parent, Popular, Inc. (BPOP) to modify and extend the main commercial agreements which had an initial term ending in 2025. These include a 10-year extension of the Merchant Acquiring Independent Sales Organization Agreement (the "ISO Agreement"), a 5-year extension of the ATH Network Participation Agreement and a 3-year extension of the Master Services Agreement. The ISO Agreement, which sets our merchant acquiring relationship with BPPR, will now include revenue sharing provisions with BPPR. The MSA modifications include the elimination of the exclusivity requirement, the inclusion of annual MSA minimums through 2028 and adjustments to the existing CPI pricing escalator clause. Additionally, Evertec and Evertec Group signed a definitive agreement to sell BPPR certain assets at a price of approximately $197 million. BPPR will pay the purchase price in Evertec stock. The assets included as part of the sale are tied to technology services provided exclusively to BPPR and that are currently reported as part of Evertec's Business Solutions segment. The management of infrastructure, information security and communications will continue to be supported by Evertec through its Managed Service Provider (MSP) business offering pursuant to the MSA.

16:07 EST Rocket Companies sees Q1 closed loan volume $52B-$57B - Sees Q1 Net rate lock volume of between $50B-$57B; Gain on sale margins of 2.80% to 3.10%.

16:05 EST Bridge Investment names Katie Elsnab CFO - Bridge Investment Group announced that Chad Briggs, Chief Financial Officer of the Company, has decided to retire effective May 31, 2022. Upon Mr. Briggs' retirement, Bridge is pleased to announce that Katie Elsnab, Bridge's current Chief Accounting Officer and Corporate Controller, will assume the role of CFO. Executive Chairman, Robert Morse remarked "On behalf of everyone at Bridge, I thank Chad for his critical role in the formation and success of our company. Chad has been a trusted and valuable leader since joining our firm in 2010. In addition, Chad is credited with building the foundation of our strong finance team and retires knowing Bridge is very well positioned for continued success. We wish him all the best in his retirement."

16:01 EST Prologis to raise annual dividend 25% to $3.16 per share - The Board of Directors of Prologis approved a plan to raise the company's annualized dividend level by 25% to $3.16 per share of common stock. The board declared a regular cash dividend for the quarter ending March 31, 2022, on the following securities: A dividend of 79c per share of the company's common stock, payable on March 31 to common stockholders of record at the close of business on March 18; and A dividend of $1.0675 per share of the company's 8.54% Series Q Cumulative Redeemable Preferred Stock, payable on March 31 to Series Q stockholders of record at the close of business on March 18.

15:34 EST DoubleVerify, Comscore to partner on verification, audience measurement solution - DoubleVerify (DV) and Comscore (SCOR) announced a preferred partnership between the two to develop "a best-in-class, integrated media quality verification and audience measurement solution to allow advertisers to seamlessly measure the impact of their full media plan." DV and Comscore plan to launch the joint offering as early as the second quarter of 2022 for a select group of customers. DoubleVerify will discuss the partnership at its analyst and investor day on Friday, February 25, the company said.

14:55 EST Occidental Petroleum trading resumes

14:40 EST Pokemon Company to host 'Pokemon Presents' showcase on February 27 - The Pokemon Company will host a Pokemon Presents event broadcast on February 27, 2022. The company did not mention what announcements will be made about any current or future "Pokemon" titles. The Fly notes that all "Pokemon" games are co-published by The Pokemon Company and Nintendo. Reference Link

14:37 EST Nintendo acquires its longstanding development partner Kyoto-based SRD - In a posting on its Japanese site, Nintendo management said in a statement that it has acquired 100% interest in SRD and to make it a wholly owned subsidiary of Nintendo. According to the posting SRD is a development company that Nintendo has had a relationship with for almost 40 years. Nintendo anticipates the acquisition will serve to strengthen the management base of SRD and secure development "resources" for Nintendo. Nintendo anticipates improvements to the company's software and "efficiency." The acquisition closes on April 1. The statement notes that Kyoto-based SRD has a capital stock position of 50M yen.

14:17 EST Target's Shipt announces launches with Walgreens and 7-Eleven - Shipt, an independently operated, wholly owned subsidiary of Target (TGT), said it is "off to a breakneck start in 2022 with the launch of two new retailers that boost the number of store locations available on Shipt's marketplace by more than 40%." Shipt stated in a press release: "Available this week on the Shipt marketplace, customers now have access to thousands of over-the-counter medications, beauty, personal care, household and convenience products from health and wellness retailer Walgreens, as well as a variety of snacks, drinks and household essentials from premier name in the convenience industry retailer, 7-Eleven, Inc. Together, these launches represent an impressive show of momentum and growth for Shipt, which now boasts a diverse collection of more than 140 retail partnerships."

13:53 EST Occidental reports Q4 production of 1,189 Mboed - Occidental Petroleum said its total average global production from continuing operations of 1,189 thousand of barrels of oil equivalent per day for Q4 quarter exceeded the midpoint of guidance by 49 Mboed. Permian Resources, Rockies and Gulf of Mexico all exceeded the high end of guidance with production of 490 Mboed, 313 Mboed and 149 Mboed, respectively. International average daily production volumes came within guidance at 237 Mboed.

13:04 EST Matthews elects Alvaro Garcia-Tunon as chairman of the board - Matthews International Corporation announced that, following the company's Annual Shareholders Meeting last week, its Board of Directors elected Alvaro Garcia-Tunon as the company's Chairman of the Board. Garcia-Tunon succeeds John D. Turner, a member of the Board since 1999 and Chairman of the Board since 2010. Turner retired from the Board upon the completion of his term. "We are grateful for John's exceptional leadership," commented Joe Bartolacci, President and CEO.

12:00 EST Zevia falls -21.8% - Zevia is down -21.8%, or -$1.91 to $6.84.

12:00 EST AMTD IDEA Group falls -43.7% - AMTD IDEA Group is down -43.7%, or -$3.00 to $3.87.

12:00 EST Offerpad Solutions rises 15.0% - Offerpad Solutions is up 15.0%, or 58c to $4.44.

11:56 EST Silence Therapeutics treatment of Polycythemia Vera granted orphan designation - Silence Therapeutics' treatment of Polycythemia Vera, or PV, was granted orphan designation by the FDA, according to a post to the agency's website. Reference Link

11:31 EST Epsilon Energy board initiates quarterly dividend of 6.25c per share - The Board of Directors has approved a quarterly cash dividend of $0.0625 per common share, payable on March 31, 2022, to shareholders of record at the close of business on March 8, 2022. With the initiation of a cash dividend, Epsilon intends to pay regular quarterly dividends, with future dividend payments subject to quarterly review and approval by its Board of Directors. At this quarterly dividend rate, the annual dividend rate for the fiscal year 2022 is $0.25 per share.

11:13 EST DOJ files suit opposing Change Healthcare acquisition by UnitedHealth - In a lawsuit filed in the U.S. District Court for the District of Columbia, the U.S. Department of Justice argues that UnitedHealth Group's (UNH) proposed deal to acquire Change Healthcare (CHNG) "would allow United to co-opt its rival insurers' innovations and their competitive strategies and reduce their incentives to pursue those innovations and strategies in the first place." In addition, the DOJ seeks to block the deal on the grounds that the proposed acquisition "would also allow United to use its control over Change's technologies to disadvantage its health insurance rivals by raising their costs and denying or delaying their access to innovations and quality improvements to products and services supplied by Change." The DOJ contends in its suit: "Ultimately, this substantial lessening of competition would result in higher cost, lower quality, and less innovative commercial health insurance for employers, employees, and their families."

11:03 EST Orbital Energy unit, JV partner begin construction on 130 MW solar project - Orbital Energy Group announced that its wholly-owned subsidiary, Orbital Solar Services and its Joint Venture Partner, Jingoli Power LLC, have signed a formal Engineering, Procurement, and Construction contract and begun construction on a 130MWdc/100MWac solar farm in Alabama for Lightsource bp. The Contract calls for OSS JPOW LLC to design, engineer, and build a utility-scale solar array to be delivered in late 2022. Under the Contract terms, OSS will provide full utility-scale EPC services, including substation construction. The project will consist of 350,000 solar panels installed across 800 acres of land and will provide enough power for 20,000 homes per year. Michael Janda, OSS's President, stated, "OSS/JPOW is honored to have formally begun construction on the Black Bear Project and to start this very special relationship with the Lightsource bp team. We believe this project will solidify our mutual goals moving forward and will allow this relationship to grow over time. The satisfaction of our customer remains one of OSS's top priorities and we are honored to showcase our talent and professionalism on the Black Bear Project. We look forward to seeing this collaboration evolve with Black Bear being the first of many projects with Lightsource bp."

11:01 EST Rackspace Technology expands strategic relationship with Amazon's AWS - Rackspace Technology (RXT) is extending its Strategic Collaboration Agreement with Amazon's (AMZN) Amazon Web Services with an additional multi-year joint investment to drive customer value and innovation. The expanded agreement comes after Rackspace Technology's AWS business has grown by 250% over the past 3 years and was named 2021 AWS Migration Partner of the Year, the company said in a statement. "AWS and Rackspace Technology have jointly launched over 1,000 cloud projects enabling clients to fundamentally change how their businesses work," said Neil Emerson, Chief Commercial Officer at Rackspace Technology.

10:21 EST EMA recommends authorization of booster doses of Comirnaty for 12 and older - The EMA's human medicines committee, or CHMP, has recommended that a booster dose of the COVID-19 vaccine Comirnaty from Pfizer (PFE) and partner BioNTech (BNTX) may be given where appropriate to adolescents from 12 years of age. Comirnaty is already authorized in the EU as a 2-dose primary course in adolescents, as well as adults and children from 5 years of age, and a booster dose is currently authorized from 18 years of age. The CHMP opinion will now be forwarded to the European Commission, which will issue a final decision shortly. Reference Link

10:17 EST Europe recommends approval of Moderna COVID vaccine for ages 6-11 - The European Medicines Agency's human medicines committee has recommended granting an extension of indication for the COVID-19 vaccine Spikevax to include use in children aged 6 to 11. The vaccine, developed by Moderna (MRNA), is already approved for use in adults and children aged 12 and above. The dose of Spikevax in children from 6 to 11 years of age will be lower than that used in people aged 12 and above. As in the older age group, the vaccine is given as two injections in the muscles of the upper arm, four weeks apart. Reference Link

10:13 EST Medicago and GSK announce Health Canada approval for COVID-19 vaccine - Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline announced that Health Canada has granted approval for Covifenz, COVID-19 vaccine. This vaccine is indicated for active immunization to prevent coronavirus disease 2019, or COVID-19, caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. "The Government of Canada has a contract with Medicago to supply the COVID-19 vaccine. Medicago is committed to fulfilling this order as soon as possible," the company said. Roger Connor, President of GSK Vaccines, added, "This first approval is an important milestone in our approach of pairing GSK's well-established pandemic adjuvant with promising antigens to develop protein-based, refrigerator-stable COVID-19 vaccines to help protect people against COVID-19 disease. We look forward to working with Medicago to make the vaccine available in Canada and to progress further regulatory submissions."

10:10 EST Indonesia Energy Corporation Limited trading halted, volatility trading pause

10:03 EST Seagen, Genmab present preliminary data fom Phase 2 trial of tisotumab vedotin - Genmab A/S (GMAB) and Seagen Inc. (SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin as a monotherapy in patients with squamous cell carcinoma of the head and neck who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a manageable safety profile and promising preliminary antitumor activity in this patient population with the primary endpoint of confirmed objective response rate per investigator, achieved by 16 percent of patients. Findings will be presented as part of a plenary session at the American Society for Radiation Oncology 2022 Multidisciplinary Head and Neck Cancers Symposium on February 25. The SCCHN cohort of the innovaTV 207 trial enrolled 31 patients with a median age of 65 years whose disease progressed on or after systemic therapy. Patients received 2 milligrams/kilogram tisotumab vedotin intravenously on day one of each 21-day cycle. The secondary endpoints included disease control rate, progression-free survival per investigator and overall survival. DCR per investigator was 58.1 percent, median PFS was 4.2 months, median follow-up was 10.0 months and median OS was 9.4 months. Adverse events were consistent with the known safety profile of tisotumab vedotin: twenty-one patients developed Grade greater than or equal to3 treatment-emergent adverse events; most commonly anemia, pneumonia, and dyspnea. Incidence of treatment-emergent serious adverse events was 51.6%, and incidence of treatment-related SAEs was 6.5%.

10:01 EST AMTD International Inc - ADR trading resumes

10:00 EST Aerovate Therapeutics Inc trading resumes

10:00 EST Cian falls -17.6% - Cian is down -17.6%, or -$1.03 to $4.81.

10:00 EST BP Prudhoe Bay rises 11.7% - BP Prudhoe Bay is up 11.7%, or $1.29 to $12.32.

10:00 EST South Jersey Industries rises 37.5% - South Jersey Industries is up 37.5%, or $8.81 to $32.30.

09:47 EST Revolve Group falls -20.5% - Revolve Group is down -20.5%, or -$10.29 to $39.87.

09:47 EST Universal Compression rises 10.5% - Universal Compression is up 10.5%, or $13.18 to $138.74.

09:47 EST South Jersey Industries rises 36.9% - South Jersey Industries is up 36.9%, or $8.66 to $32.14.

09:46 EST Aerovate Therapeutics Inc trading halted, volatility trading pause

09:45 EST TransMedics Group trading resumes

09:45 EST Meihua International Medical Tech Co Ltd trading resumes

09:44 EST Yandex trading halted, volatility trading pause

09:44 EST Cepton Inc trading halted, volatility trading pause

09:44 EST IDEX Biometrics ASA (ADS) trading resumes

09:44 EST Meihua International Medical Tech Co Ltd trading halted, volatility trading pause

09:43 EST TransMedics Group trading halted, volatility trading pause

09:43 EST Ideal Power trading halted, volatility trading pause

09:41 EST SeaWorld in a 'strong' financial position, says CEO Marc Swanson

09:38 EST Patrick Industries to acquire Rockford Corporation, terms not disclosed - Rockford Corporation (ROFO) announced that it has signed a definitive agreement under which Rockford will become a wholly owned subsidiary of Patrick Industries (PATK). Rockford has notified shareholders by mail of the upcoming acquisition that Patrick Industries, Inc. anticipates completing on or around March 7, 2022. Following closing, Rockford will continue its operations as a wholly owned subsidiary of Patrick in its existing facility in Tempe, Arizona.

09:34 EST Ben's Chili Bowl selects Mobivity SmarMessage for guest connection - Ben's Chili Bowl announced it has selected Mobivity Holdings to make it easier to connect with its guests on the device they use the most. Mobivity SmartMessage helps restaurants use one-to-one text messaging to communicate with guests.

09:32 EST Citi to eliminate overdraft fees for retail bank consumers - Citi announced plans to eliminate overdraft fees, returned item fees, and overdraft protection fees by this Summer for U.S. Citi retail bank consumers. "Citi will be the only top five U.S. bank, based on assets, to completely eliminate these fees, representing its continued commitment as a top leader in banking to increase financial inclusion in underserved communities," the bank stated. "This latest enhancement is a significant step for Citi as a leader in the banking industry offering the most consumer-friendly overdraft practices. We are continuously looking for ways to utilize our industry-leading capabilities to make the financial system easier and more equitable for communities who have little or no financial buffer," added Gonzalo Luchetti, CEO of US Personal Banking at Citi.

09:30 EST Sigma Labs appoints Phillips Federal as exclusive reseller - Sigma Labs announced that it has named Phillips Federal, a Division of Phillips Corporation, as the company's exclusive reseller to the United States federal government. The purpose of the agreement is to deliver an agnostic quality monitoring and analytics solution to standardize qualification across government installations, unify various technologies and accelerate readiness, quality, scale, and supply chain options for the U.S. government. To facilitate the ability of Phillips Federal to provide testing and onsite demonstrations, Sigma Labs will install a PrintRite3D system at the Phillips Additive Innovation Center inside the Army Center of Excellence for Advanced Manufacturing at Rock Island Arsenal Joint Manufacturing and Technology Center. Phillips' Additive Innovation Center is a dedicated space utilized in conjunction with their collaborative work with the Department of Defense (DoD) to educate, inspire, and redefine the capabilities of additive manufacturing. The PrintRite3D system will be installed on an EOS M290 DMLS machine to be used for demonstration, training and education of DoD personnel on the benefits of in-process monitoring.

09:27 EST DigiMax updates mobile app launch progress - DIGIMAX GLOBAL is pleased to announce that it has now surpassed 1,000 downloads of the mobile-app version of CryptoHawk AI, enjoying a 4.9 rating on both Apple and Google App Stores with more than 150 ratings within two weeks of our launch. The number of downloads per day continues accelerating as various marketing campaigns are gaining traction. Downloading the App is as easy as searching for CryptoHawk on either Apple or Google App stores. CryptoHawk AI is seeing increasing views, shares, and followers on Twitter, Instagram, TikTok, and Reddit. On Reddit alone in the past week, a single ad enjoyed more than 800,000 impressions over 7 days. DigiMax is also pleased to announce that it is finally able to make the world's third largest token exchange, BitGet, accessible from the CryptoHawk AI app. BitGet will be offered as a Preferred Partner trading platform in the app within the next week. In the opposite direction, CryptoHawk AI will be directly accessible from the BitGet trading site. Both companies will now also feature the other's service on their websites and apps. DigiMax expects to launch, and re-launch, relationships with other high-profile influencers and market participants over the next 60 days.

09:24 EST American Resources furthers feasibility study for lithium, colbat reserves - American Resources Corporation announced that the Company's subsidiary, American Rare Earth LLC, is furthering its feasibility study of the lithium, cobalt and rare earth elements that are present in its various deposits among its 20,000 controlled acres. Through its parent company and affiliates, American Rare Earth has been able to secure approximately 20,000 acres of mineral deposits throughout Central Appalachia that has demonstrated the potential to contain lithium and cobalt as part of its overall mix of elements, primarily through coal waste deposits and waste streams that possess other favorable cost attributes when processed with its patented electrolysis technology. American Rare Earth will utilize its "process" technology to extract the lithium, cobalt and rare earth elements from its controlled feedstocks, and then purify these elements by way of its patented chromatography technology at its initial facility located in Noblesville, Indiana. American Resources, which is currently in the design and implementation phase of its Wyoming County, West Virginia site that was preliminarily approved for a $45 million tax exempt bond offering, is integrating specific mineral spirals and its patented electrolysis technology directly into its high value metallurgical carbon facilities to process waste streams coming out of the processing plant before certain material is landfilled. In the process, the Company will be extracting targeted elements that are present as well as using certain negative particulates that are present in existing landfilled coal waste streams to be used in the Company's electrolysis process. This step further reduces the chemical needs by using natural materials that are a common byproduct of the coal industry. American Rare Earth will begin the next steps of the feasibility study program by identifying the controlled sites with the highest concentration of lithium and cobalt as well as other key characteristics that maximizes the value of its electrolysis technology. From there, the Company will commercially develop these deposits to be used as additional feedstock for its Indiana-based rare earth and battery metals isolation and purification facility.

09:19 EST Terreno Realty acquires three industrial properties in Washington for $13M - Terreno Realty acquired three industrial properties in Bellevue, Washington for a purchase price of approximately $13M.

09:16 EST Adial Pharmaceuticals completes last visit in ONWARD Phase 3 trial - Adial Pharmaceuticals announced that the final patient has completed the last dose and last clinical visit in the Company's ongoing ONWARD Phase 3 trial. ONWARD is evaluating the efficacy, safety and tolerability of AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.

09:13 EST Chevron and Iwatani to build 30 hydrogen fueling stations in California - Chevron U.S.A. and Iwatani Corporation of America or ICA, a wholly owned subsidiary company of Iwatani Corporation announced an agreement to co-develop and construct 30 hydrogen fueling sites in California by 2026. As part of the agreement, Chevron plans to fund construction of the sites, which are expected to be located at Chevron-branded retail locations across the state. The stations will initially fuel light-duty vehicles while retaining the flexibility to service heavy-duty vehicles over the long term. Iwatani will operate and maintain the hydrogen fueling sites and provide hydrogen supply and transportation logistics services. Chevron plans to supply a portion of the fueling sites with excess hydrogen production capacity at its Richmond Refinery and future hydrogen production from pilot projects in Northern California. "Chevron believes that hydrogen has the potential to assist in lowering the carbon emissions of the transportation sector and other hard-to-decarbonize industries," said Andy Walz, president of Americas Fuels & Lubricants for Chevron. "We are excited to work with Iwatani to advance the entire hydrogen transportation value chain from production to consumer purchase in order to help our customers lower their lifecycle transportation carbon intensities."

09:10 EST SenesTech's ContraPest rat control product deployed at correctional facility - SenesTech announced the deployment of ContraPest at a correctional facility, the first such deployment into a large customer segment. This 2,500 bed, medium security facility encompasses approximately 20 acres and a dozen plus structures and has the added challenge of being near waste transfer facilities. This is the first known deployment by a pest management professional into a major correctional facility. Deployed in traditional bait boxes, ContraPest targets the reproductive capabilities of both sexes in rat populations. ContraPest is available for use in all 50 states and the District of Columbia.

09:09 EST ModivCare appoints Nathan Vaughn as Chief Diversity Officer - Modivcare announced that the company has appointed Nathan Vaughn as Chief Diversity Officer and Vice President, Talent Acquisition. In the role of Chief Diversity Officer, Mr. Vaughn will work closely with executive leadership and team members across the organization to ensure that the Company creates an environment where everyone belongs and reflects the diversity of the patients we serve.

09:08 EST Nikola targets delivery of Nikola Tre BEVs to customers in Q2 - The company said, "On December 17, 2021, we delivered the first two Nikola Tre BEVs to TTSI in California as a part of a three-month pilot program. Since placing the trucks into service with TTSI, the trucks have hauled multiple loads per day and logged over 4,500 miles combined. The trucks have completed a 204-mile journey on a single charge, the longest range of any BEV TTSI has tested. We are pleased with the pilot results and look forward to delivering saleable Nikola Tre BEVs to customers in the second quarter of 2022."

09:06 EST Nikola expects Phase 1 of Coolidge, Arizona facility complete by Q1-end - The company said, "Phase 1 of the Coolidge, Arizona facility provides us with a production capacity of 2,500 trucks for 2022. We have begun construction of the Phase 2 assembly expansion area, which is expected to be completed in Q1 2023 and provide us with a production capacity of up to 20,000-trucks per year on two shifts. Our Ulm, Germany manufacturing facility on IVECO's industrial complex is complete. The facility is capable of producing 2,000 trucks per year and is expandable to 10,000 trucks per year. In 2022, we expect to build and deliver 25 trucks to the Hamburg Port Authority."

09:04 EST Shineco enters strategic cooperation agreement with XHPC - Shineco announced that the Company entered into a strategic cooperation agreement with Beijing Xihuan Psychological Consulting, a Beijing-based comprehensive psychological consulting company, on February 21, 2022 to jointly build an industry-university-research-medical collaborative platform for psychological rehabilitation of tumor patients. Shineco and XHPC plan to use the Platform to conduct research on critical topics, introduce the results of relevant research into the Company's tumor clinical treatment system, and improve the development of Shineco's digital tumor diagnosis and treatment. XHPC is a professional integrated psychological consulting company, providing one-stop social psychological solutions for enterprises, institutions, and certain social groups, such as psychological care organizations for youth. Over the years, XHPC has built a system to tackle the challenges of psychological and behavioral problems through psychological counseling, corporate employee assistance program services, and psychological evaluation, which effectively promotes the healthy development of enterprises and improves the mental health of their employees. The modern treatment of tumors has evolved into a multi-disciplinary and comprehensive treatment to involve multiple factors, such as mental, physical, and societal. The cooperation between the two parties will focus on the mental health of tumor patients. Leveraging both parties' respective advantages, the two parties expect to build an industry-university-research-medical platform and introduce the results of relevant research into Shineco's tumor clinical treatment system by conducting research on the mental health and intervention of tumors. By establishing an early intervention collaboration mechanism, the parties aim to create a regional integrated and collaborative diagnosis and treatment model to help improve the rate of early diagnosis and early treatment of tumor diseases.

09:04 EST Nikola targets delivery of 300-500 production Nikola Tre BEVs in 2022 - Nikola looks forward to achieving the following milestones in 2022: Deliver 300 - 500 production Nikola Tre BEVs to customers; Successful pilot testing of Tre FCEV alpha trucks with AB, TTSI and others; Build, test, and validate Tre FCEV beta trucks; Announce location, break ground, and commence construction of the first hydrogen production hub in Arizona; Announce two or more dispensing station partners in California.

09:01 EST Broadcom announces PCIe Gen 5.0 portfolio - Broadcom announced its broad, industry-leading PCIe Gen 5.0 portfolio is setting the foundation for the ecosystem to build high-performance, next-generation servers. Broadcom PCIe Gen 5.0 SerDes, switches and custom silicon products, which are now available to OEMs, ODMs, and cloud providers, are actively being tested and demonstrated for wide-scale interoperability.

08:58 EST Quantum Computing, QPhoton enter exclusive marketing agreement - Quantum Computing announced their business partnership and exclusive marketing agreement with QPhoton, Inc., a leading innovator in the quantum photonic technology space. The companies will work together to merge QCI's quantum software solution, Qatalyst, with QPhoton's advanced photonic quantum technologies for its application to QCI-specific solutions.

08:57 EST Wayfair sees Q1 CapEx $95M-$105M

08:55 EST Omniq announces $1M purchase order - OMNIQ Corp. has received a $1.0 million purchase order from one of the largest U.S.-based less-than-truckload firms. The purchase order calls for additional support services as part of on-going mobility platform upgrade.

08:53 EST Versus Systems announces pricing of public offering - Versus Systems announced the pricing of its public offering of 4,375,000 units for gross proceeds of USD $7,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by Versus. Each unit consists of one common share, no par value per share, and one warrant to purchase one common share, at a public offering price of $1.60 per unit and a warrant exercise price of $1.92. All of the shares and warrants included in this offering are being sold by Versus. In addition, Versus has granted the underwriters a 30-day option to purchase up to an additional 656,250 common shares and/or 656,250 additional warrants at the public offering price, in any combination thereof, on the same terms as the other common shares and warrants being purchased by the underwriters from Versus. The offering is subject to customary closing conditions and is expected to close on February 28, 2022. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. D.A. Davidson & Co. and H.C. Wainwright & Co., LLC are acting as joint book-running managers for this offering and as representatives of the underwriters in this offering.

08:51 EST Eos Energy invited to submit Part II loan application by DOE - Eos Energy Enterprises announced it has advanced through Part I of the U.S. Department of Energy's Renewable Energy and Efficient Energy Loan Program. To be invited to submit a Part II loan application, Eos had to demonstrate to the DOE that Eos's Znyth battery employs innovative technology and avoids or reduces greenhouse gas emissions. Eos will now proceed to Part II of the loan application process in support of the previously announced expansion of its Turtle Creek domestic manufacturing facility to more than triple capacity to 800MWh by year-end. Located outside of Pittsburgh, PA, the expanded Turtle Creek facility is expected to create more than 125 green jobs and provide Eos with an additional 46,000 square feet of space to expand production of its Znyth aqueous zinc battery technology as customer demand continues to grow.

08:50 EST Trust Stamp launches Identity Orchestration Platform - Trust Stamp announces the launch of its end-to-end Identity Orchestration Platform, which streamlines delivery and implementation of the Company's proven technologies through a low-code approach. Trust Stamp's powerful identity platform enables clients to transform security, privacy, and usability in digital operations with a range of leading AI-powered technologies including biometric, document and liveness verification, as well as data-protection and more, in order to support robust identity frameworks that can be established, augmented, and modified with agility and speed.

08:49 EST Modular Medical appoints James Besser as CEO - Modular Medical announced that its board of directors has appointed James "Jeb" Besser as Chief Executive Officer. Besser, a company development and capital markets veteran, has served 23 years as managing member of Manchester Management , the Company's largest outside shareholder and development partner since its inception. Lynn Vos, the Company's CEO since August of 2021, will remain on the board of directors of the Company and continue an active role in the marketing and commercialization strategy for the Company, as the Company focuses on preparing and submitting to the FDA a 510k application for its next generation MODD1 insulin pump. The Company anticipates this submission to take place during Q2 of this year. "Having been involved with the development of Modular Medical since its inception, I believe strongly in the Company and its mission to expand access to wearable insulin delivery technology," said Besser. "This is a very exciting time in our lifecycle, and I would like to thank Lynn Vos for her role in managing the recent capital raise and Nasdaq uplist and for helping round out our board. I look forward to working with her going forward."

08:47 EST Kinross Gold completes acquisition of Great Bear Resources - Kinross Gold Corporation is pleased to announce that it has completed the previously announced plan of arrangement to acquire all of the issued and outstanding shares of Great Bear Resources. Under the terms of the Arrangement, Great Bear shareholders were provided the right to elect to receive C$29.00 in cash for each Great Bear common share or 3.8564 Kinross common shares per Great Bear Share, both subject to pro-ration to a maximum cash consideration of approximately US$1.1 billion and a maximum of 80,773,353 Kinross Shares. Based on valid elections received by the election deadline, Great Bear shareholders who elected to receive cash were subject to pro-ration and will receive approximately C$25.80 in cash and approximately 0.4257 Kinross Shares per Great Bear Share. Great Bear shareholders who elected to receive the shares were not subject to pro-ration. The Arrangement also includes a payment of contingent consideration in the form of one contingent value right per Great Bear Share that may be exchanged for 0.1330 of a Kinross Share per Great Bear Share. The contingent consideration will be payable in connection with Kinross' public announcement of commercial production at the Dixie project, provided that a cumulative total of at least 8.5 million gold ounces of mineral reserves and measured and indicated mineral resources are disclosed. The CVRs are transferable and have a term of 10 years. In aggregate, Kinross will pay approximately C$1.35 billion in cash and issue approximately 49.3 million Kinross shares and approximately 59.3 million CVRs to Great Bear securityholders under the Arrangement. Subsequent to December 31, 2021, Kinross drew down US$1.1 billion from its US$1.5 billion revolving credit facility to finance the cash portion of the Arrangement. The shares of Great Bear are expected to be delisted from the TSX Venture Exchange at market close on February 25, 2022. Following the delisting, Kinross intends to apply for Great Bear to cease to be a reporting issuer under applicable Canadian securities laws.

08:45 EST Discovery says on track to close WarnerMedia merger agreement in early Q2 - Says expects foreign exchange to have a $90-100M impact on revenues in FY22. Says on track to close WarnerMedia merger agreement in early Q2. Says does not see impact from Russia-Ukraine situation. Says library is as big as Netflix. Says churn is getting better in Europe. Says has been focusing on cost ahead of closing on Warner deal. Comments taken from Q4 earnings conference call.

08:43 EST Femsa announces annual shareholders meeting - Fomento Economico Mexicano announces it will hold its Annual Ordinary Shareholders' Meeting on April 8, 2022 in Monterrey, Nuevo Leon, Mexico. A copy of the formal call for the Shareholders' Meeting will be available in the following link in the upcoming days The record date for FEMSA's ADS holders in the US will be March 14, 2022. In line with investor feedback and with the express intention of enhancing accountability to shareholders and increasing independent Board oversight, as part of the upcoming Shareholders' Meeting, the board of directors of FEMSA announces the following actions and commitments to enrich its corporate governance profile: Strengthening Board Accountability to Shareholders: Shareholders will have the ability to vote on directors individually, rather than as a slate, beginning with this Shareholders' Meeting. Increasing Influence of Independent Directors: Continue refreshment and right-sizing of our Board, reducing board size to a target range of between 14 and 15 directors by 2023, a decrease from 18 directors in 2021, and 21 directors in 2018. By 2023 and once our target size is met, independent directors will comprise no less than 40% of the Board. Increasing Oversight Role of Independent Directors on Key Committees: The Audit Committee and the Corporate Practices Committee will continue to support the board of directors by providing vital independent oversight in their respective areas of focus. In addition, as part of our board renewal process, the Corporate Practices Committee will be renamed Corporate Practices and Nomination Committee, and will expand oversight to add to its responsibilities, the following: Evaluation and nomination of candidates for Series D directors, Appropriate board composition by ensuring the board includes directors with the skills, experiences and capabilities required to provide effective oversight, and Provide to shareholders a summary of the evaluation and nomination process for directors. The Strategy and Finance Committee will add independent operational oversight to its purview: A majority of the Committee will be independent directors. The Committee will provide specific oversight on transformational initiatives, further increasing the involvement and time commitment of directors on operational matters and complementing the role of Senior Management. Governance priorities post-2022: Continue enhancing the Board's independent oversight and effectiveness by: Balancing institutional knowledge with fresh perspective by adding new independent directors. Adding additional expertise on relevant new-business areas such as Digital and E-commerce, Sustainability among others. Further enhancing Board gender diversity beyond our current level of 22%, and relevant ESG expertise in line with FEMSA's focus on, commitment to, and leadership of ESG initiatives critical to our success. Ensure Board focus and responsiveness by adopting limits on directors' outside board commitments. Bolster outreach to shareholders to continue to gather their input as we further enhance our governance.

08:41 EST Apollo Global launches Sustainable Investing Platform - Apollo announced the launch of a comprehensive sustainable investing platform focused on financing and investing in the energy transition and decarbonization of industry. Across asset classes, Apollo targets deploying $50 billion in clean energy and climate capital over the next five years and sees the opportunity to deploy more than $100 billion by 2030. With approximately $4.5 trillion1 annually in investments needed to achieve global net zero by 2050, Apollo aims to be a leading capital partner to companies and communities globally. Apollo's sustainable investing platform will leverage the Firm's deep expertise in the key sectors driving today's energy transition and decarbonization. Over the past five years, Apollo has deployed over $19 billion into energy transition and sustainability-related investments, supporting companies and projects across clean energy and infrastructure, including offshore and onshore wind, solar, storage, renewable fuels, electric vehicles as well as a wide range of technologies to facilitate decarbonization. Apollo has also played an active role in helping to finance the transformation of traditional energy companies toward their decarbonization goals.

08:38 EST PAVmed appoints Shaun O'Neil as COO - PAVmed PAVM and parent of cancer prevention company Lucid Diagnostics ( LUCD), announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section16a of the Securities Exchange Act of 1934.

08:36 EST Motus GI Holdings granted 180-day extension to meet NASDAQ requirement - Motus GI Holdings announced that the Company received written notification from the Listing Qualification Department of The NASDAQ Capital Market granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company now has until August 22, 2022 to meet the requirement. Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market under the symbol "MOTS". If at any time until August 22, 2022, the bid price of the Company's Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Rule, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) on August 24, 2021 and was given until February 21, 2022 to regain compliance. If the Company does not meet the minimum bid requirement during the additional 180-day extension, Nasdaq will provide written notification to the Company that its Common Stock will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq Hearings Panel. The Company would remain listed pending the Panel's decision. There can be no assurance that if the Company does appeal a subsequent delisting determination, that such appeal would be successful.

08:35 EST Clarus Therapeutics announces strategic partnerships for JATENZO - Clarus Therapeutics Holdings announced that it has partnered with Vault Health, an innovative healthcare company bringing clinical care to people's homes. Clarus also announced the launch of its new technology-enabled patient access platform for JATENZO oral softgel capsules, supported by AssistRx's access and fulfillment solution, CoAssist, which streamlines the prescription process for healthcare providers and home delivery of JATENZO for patients.

08:34 EST Agora to showcase real-tim future of work at 4YFN - Agora, Inc. returns to the GSMA's leading start-up and innovation platform, 4YFN. 4YFN is the world's largest exhibition for the mobile industry, with a mission to support startups, investors and companies to connect and launch new business ventures together. In a session titled, The Workplace2026: The Future of Work, Collaboration, and Connectivity, the Agora team led by Wyatt Oren, Strategic Sales Manager, and Blaise Thomas, Startup Advocate, will explore how our work is evolving and what your workday looks like in 2026 - from the metaverse to IoT, human collaboration is undergoing a major transformation.

08:34 EST Stericycle sees five-year CAGR of 3%-5% - Expects to generate at least $400M in annual free cash flow between 2024 and 2025, primarily driven by operating margin expansion. Sees achieving a credit agreement defined debt leverage ratio below 3 times between 2022 and 2023.

08:32 EST Whole Earth Brands launches strategic ESG framework - Whole Earth Brands announced the launch of its environmental, social, and governance framework and strategic goal areas. Centered on three pillars - producing sustainably, supporting thriving workers and communities, and enabling healthier lifestyles - the Whole Earth Brands ESG framework seeks to further and positively influence a host of important issues involving the company, its employees and the effect its production facilities can have on the environment and climate. Whole Earth Brands determined these pillars after a formal assessment process that included an outside consultant, internal interviews and external research.

08:30 EST Wayfair sees more steady hiring pace from here

08:29 EST Wayfair sees 27%-28% as 'sustainable' gross margin rate - Sees low end of 27%-28% range for Q1.

08:27 EST Wayfair: Q1 gross revenue to-date down in low teens y/y

08:26 EST TransUnion introduces Point-of-Sale suite of solutions - Up to 100 million U.S. adults have used buy now pay later loans at least once in the past 12 months, but financial institutions currently do not have access to the valuable insights generated when consumers open and repay these new debt obligations. To help promote financial inclusion opportunities for this growing population, and allow the financial community to accurately capture credit behaviors of consumers using such loans and other point-of-sale installment products, TransUnion introduced its new Point-of-Sale suite of solutions.TransUnion is launching the capability to receive point-of-sale lender trades through the traditional credit reporting process, with specific Metro 2reporting guidance that ensures FCRA compliance. The goal is to have a single standard for lenders to report data and accelerate adoption by lenders and scoring providers in the future. The information will be tagged and filtered into a new partitioned part of TransUnion's core credit file. Users of TransUnion credit data will be able to opt-in to receive these tradelines as part of their existing credit data delivery. Default credit report delivery, which feeds existing scoring models, will remain unaffected. Over time, as the industry works to enhance models with these data, it is expected that many lenders will choose to use the information in addition to their existing models to help expand their buy boxes - accelerating the consumer impact.

08:25 EST Home Point Capital board authorizes $8M share repurchase program - Home Point Capital's board of directors has (i) declared a cash dividend of 4c per share for the fourth quarter of 2021, payable on or about March 24, 2022 to all stockholders of record at the close of business on March 10, 2022 and (ii) authorized a stock repurchase program whereby the company may repurchase up to a total of $8M of its issued and outstanding common stock, par value $0.0000000072 per share, from time to time until the program's expiration on December 31, 2022 on the open market or in privately negotiated transactions.

08:24 EST Reservoir Media enters deal for catalog of Larry Smith - Reservoir Media announced a deal for a stake in the catalog of legendary hip-hop producer and songwriter Larry Smith. The deal includes the late Smith's collaborations with seminal rap group Whodini, 1984's Escape and 1986's Back in Black. As one of the most influential producers in the early days of hip-hop, Smith helped propel the genre into the mainstream. From the late 70s through the mid 80s, his innovative work with Whodini, Run-D.M.C., and Kurtis Blow sold millions of records and was at the forefront of shaping the evolution of hip-hop.

08:21 EST Principal Solar announces completion of Regulation A Plus Equity offering - Principal Solar announced the successful, final closing of its Regulation A Plus equity offering. The Offering, which commenced on November 25, 2020, and concluded on February 16, 2022, raised gross proceeds of US$8.65 million through the sale of 96.6 million shares of the Company's common stock at US$0.0895 per share. The proceeds of the Offering have been used to pay down outstanding debt and expensive convertible notes as well as to invest in or acquire oil and gas leases, oil and gas extraction technologies, operating companies with existing revenues, and electric vehicle technologies.

08:19 EST Rhythm Pharmaceuticals announces FDA extension of review period for IMCIVREE - Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has extended by three months the review period for the supplemental New Drug Application for IMCIVREE for the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with Bardet-Biedl Syndrome or Alstrom syndrome. On February 23, the FDA notified the Company that the Prescription Drug User Fee Act goal date has been revised to June 16, 2022. The FDA this month requested additional subgroup analyses of the clinical efficacy data from Rhythm's Phase 3 pivotal trial in BBS and Alstrom syndrome. No new data were requested. The additional information has been deemed a 'major amendment' to the sNDA, which requires additional time to review. The major amendment did not include any information relating to the safety or manufacturing of setmelanotide. "While we are disappointed by this delay, we believe these additional subgroup analyses are supportive of setmelanotide's potential to address the early-onset, severe obesity and hyperphagia that characterize both BBS and Alstrom syndrome," said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. "We recognize patients living with BBS and Alstrom syndrome have no approved therapies, and we will continue our intense preparations for launch in anticipation of potential regulatory approval."

08:18 EST Wayfair: Outgoing CTO Jim Miller to stay on as adviser until June

08:16 EST Southwest Gas urges shareholders to reject Icahn's tender offer - Southwest Gas confirmed that an affiliate of Carl Icahn extended its tender offer to acquire any and all outstanding common shares of the Company for $75.00 per share in cash. As previously announced, Southwest Gas' Board of Directors rejected Icahn's unsolicited, inadequate, structurally coercive, highly conditional and illusory tender offer. Accordingly, the Board continues to recommend that stockholders not tender any of their shares into the Offer. Southwest Gas issued the following statement: "The Southwest Gas Board and management team are executing a clear and detailed strategy to create value and deliver attractive, risk-adjusted total returns comprising stable earnings and a meaningful dividend. We continue to recommend that stockholders reject Mr. Icahn's Tender Offer, which is highly illusory, undervalues the company, has no certainty of completion and is not in the best interests of Southwest Gas stockholders."

08:16 EST Femasys appoints Dov Elefant to CFO - Femasys announced the appointment of Dov Elefant to chief financial officer, to be effective February 28, 2022. Mr. Elefant has 25 years of financial management experience at both public and private biopharmaceutical companies. Most recently, he was the vice president and CFO of Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer drugs.

08:14 EST Dentsply Sirona appoints Dorothea Wenzel to board - DENTSPLY SIRONA announced that Dr. Dorothea Wenzel has been appointed to its Board of Directors, increasing the size of its Board from ten to eleven members. Dr. Wenzel has also been appointed as a member of the Audit and Finance Committee. Dr. Dorothea Wenzel served for Merck KGaA, Darmstadt, Germany, from June 2004 to August 2021, most recently since 2019 as Executive Vice President and Head of the Surface Solutions Business Unit.

08:12 EST Agilent and UVM establish Agilent Laboratory for Chemical Analysis - Agilent Technologies and the University of Vermont, UVM, announced the establishment of the Agilent Laboratory for Chemical Analysis, ALCA. The facility will be a hub for advanced instrumentation that will allow students, institutional colleagues, industrial partners, and regional high-tech start-ups to study the composition and structure of chemical samples. It is intended as a shared educational and research space that will play a central role in the education and training of undergraduate and graduate students at UVM, while also serving as a valuable technology resource to local and regional businesses. "Agilent is extremely pleased to support UVM in the development of this innovative research facility," said Mike McMullen, Agilent president and CEO. "It's another example of Agilent's commitment to advancing scientific understanding and at the same time supporting UVM and the local community." "This new state-of-the-art instrumentation laboratory will fulfill a primary need in academia, where we have an obligation

08:11 EST Centessa doses first subject in Phase 3 ACTION study - Centessa Pharmaceuticals announced it has started dosing of the first subject in its pivotal Phase 3 clinical trial evaluating lixivaptan as a potential treatment for Autosomal Dominant Polycystic Kidney Disease. The trial is expected to enroll approximately 1,350 subjects across more than 200 sites in over 20 countries. The Company anticipates completing enrollment in the second half of 2023 and, if results are supportive, plans to submit a New Drug Application after completion of the one-year double-blind portion of the study. Dosing of the first subject in the ACTION Study is the trigger for payment of the contingent value rights originally issued to former shareholders and option holders of Palladio in January 2021 in connection with Centessa's acquisition of Palladio. The CVR will be settled in newly issued ADSs of Centessa.

08:09 EST Orezone announces drill results from Bombore Gold project - Orezone Gold Corporation is pleased to provide drill results from the first 6 holes of the Phase II program at P17S-NE extension along the P17 mineralized trend at the Bombore Gold Project, located in Burkina Faso. The Phase II program is a follow up to Phase I which intersected several high-grade zones related to a folded mineralized granodiorite that extends outside of the existing reserves and resources at P17S-NE. Continuing the success from the Phase I program, the initial results from the Phase II program confirm the continuity of mineralization at surface and the extension down dip along the P17S-NE zone. The system remains open at depth and to the north. Drilling Highlights: 12.20 m of 10.01 g/t Au from 245.80 m in hole BBD1081; 6.00 m of 2.41 g/t Au from 79 m in hole BBD1081; 14.00 m of 1.21 g/t Au from 33 m in hole BBD1077; 6.00 m of 2.16 g/t Au from 51 m in hole BBD1077; 7.00 m of 2.63 g/t Au from 117 m in hole BBD1077; 13.00 m of 1.86 g/t Au from 5 m in hole BBD1078; 7.00 m of 1.56 g/t Au from 47 m in hole BBD1079; 15.10 m of 1.27 g/t Au from 13 m in hole BBD1080. Commenting on the results, Patrick Downey, President and CEO stated, "Hole BD1081 was a significant step-out hole and is one of the best holes drilled to date at P17S. It confirms the down-dip continuity and extends the system further towards P17. Also of significance are the multiple near surface intercepts from this recent drill program. These results confirm the consistency and repeatability of the folding patterns both near surface and down plunge indicating a robust and continuous near surface mineralized system. Our drilling in 2021 and 2022 has been outside of the current reserve pit and intersected zones that are still open at depth and now warrant drilling beyond the current Phase II program.

08:08 EST Element Fleet launches Arc by Element - Element Fleet Management announced the launch of Arc by Element - an end-to-end electric vehicle fleet offering designed to help clients navigate and simplify the complex transition from internal combustion engine vehicles to EVs.

08:07 EST AbbVie announces provincial reimbursement for Venclexta in Canada - AbbVie announced that Alberta, Saskatchewan, British Columbia, and Manitoba now reimburse Venclexta in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, or CLL. The regimen combines six 28-day cycles of obinutuzumab with 12 cycles of Venclexta. The combination treatment is also listed on the Drug Benefit List in the Non-Insured Health Benefits Program and has been on Quebec's Liste des medicaments since last November, AbbVie noted.

08:06 EST Equinix names Nicole Collins as Chief Transformation Officer - Equinix (EQIX) announced the appointment of Nicole Collins to the position of Chief Transformation Officer. In this role, Collins will serve as a member of the Equinix Executive Team and report directly to CEO Charles Meyers. Prior to joining Equinix, Collins served in a variety of leadership positions over a span of eight years at VMware (VMW).

08:05 EST Thorne HealthTech, UFC extend marketing partnership - UFC and Thorne Health Tech announced a multi-year extension of their global marketing partnership. Thorne remains the Official Sports Performance Nutrition Partner of UFC and an official partner of the UFC Performance Institute, the world's first Mixed Martial Arts multi-disciplinary research, innovation, and training center.

08:03 EST AbbVie says second Phase 3 study confirms upadacitinib improved Crohn's outcomes - AbbVie announced "positive" top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib achieved both primary endpoints of clinical remission and endoscopic response at week 12. U-EXCEL is the second of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease who had an inadequate response or were intolerant to conventional or biologic therapy. U-EXCEL included the same primary and key secondary endpoints as U-EXCEED, with clinical remission measured by the Crohn's Disease Activity Index and by the patient-reported symptoms of stool frequency/abdominal pain. A significantly greater proportion of patients treated with a 12-week induction regimen of upadacitinib 45 mg daily achieved clinical remission per CDAI at week 12 compared to placebo, 49% versus 29%. Similar results were observed with clinical remission per SF/AP. At week 12, a significantly greater proportion of patients treated with upadacitinib 45 mg achieved endoscopic response compared to the placebo group. Consistent with results from the U-EXCEED induction study, a significantly higher proportion of patients receiving upadacitinib 45 mg also achieved steroid-free clinical remission per CDAI and per SF/AP compared to placebo at week 12 among patients taking corticosteroids at baseline. Early symptom improvement measured by CR-100 at week two as well as clinical remission at week four were also achieved by a significantly higher proportion of patients receiving upadacitinib 45 mg.

08:02 EST WW names Sima Sistani as CEO, effective March 21 - WW International announced that Sima Sistani, the Co-Founder and former CEO of Houseparty and a senior leader at Epic Games, will join the company as CEO, effective March 21st. In addition, she will join the WW Board of Directors on the same date. Her appointment follows Mindy Grossman's previously announced decision to step down as CEO and President at the end of Q1. To ensure a seamless transition, Mindy will now depart WW on March 18th. Sistani co-founded Houseparty in 2016 as a face-to-face synchronous social network with the intention of bringing empathy to online communication. Under her leadership, it grew to a community of over 150M users and was acquired by Epic Games in 2019. At Epic, she serves as the senior executive leading social gameplay and feature development for their gaming products including Fortnite. Previously, Sistani led mobile growth operations at Yahoo! during a pivotal transition to mobile-first. After Yahoo! acquired Tumblr in 2013, Sistani became their first Head of Media propelling them to become the fastest-growing social network in under six months.

08:02 EST Magnite selected by GroupM for GroupM Premium Marketplace - Magnite has been chosen to power the GroupM Premium Marketplace in the US and Canada as well as a global preferred technology partner. GroupM will consolidate its programmatic media buying across omnichannel environments including CTV, digital video, and display within Magnite in the US and Canada. GroupM will leverage Magnite on a preferred basis globally across EMEA, APAC and LATAM.

07:59 EST Troika Media to acquire Converge Direct for $125M - Troika Media Group, announced that it has signed a definitive purchase agreement to acquire Converge Direct LLC and its affiliates, a leading independent marketing and customer acquisition business for $125 million. The Acquisition has been unanimously approved by the Boards of Directors and the majority of shareholders of both Troika and Converge. The transaction is expected to close on or before March 15th, subject to the satisfaction of customary closing conditions. Since its formation in 2006, Converge and its affiliates have grown to approximately $300 million in annualized revenue and $23 million in adjusted EBITDA for the year ending December 31, 2021. Converge is a leading independent performance marketing and managed services business. Converge provides to customer acquisition services utilizing a broad range of engagement channels in the digital, offline and emerging media sectors. Converge utilizes a business intelligence centric approach to its media strategy, planning and buying to deliver its clients' customer acquisition targets and KPIs to achieve scale, efficiency and/or on time lead fulfillment. Converge's proprietary solutions and HELIX's business intelligent software offers clients best-in-class customer acquisition metrics. Converge's 85 full time employees are expected to join Troika upon the closing of the acquisition and the combined company will have approximately 200 full time employees. Troika has signed a binding purchase agreement to acquire Converge for total consideration of $125 million. Troika will fund the transaction with a combination of new debt financing, a restricted stock grant and cash on hand at closing. Troika has a commitment with respect to the majority of the purchase price in the form a senior secured credit facility. Upon closing, the senior management team of Converge will enter into long-term Employment Agreements and take an active leadership role in the combined business. Sid Toama, formerly Chief Operating Officer of Converge, will join Troika's Board of Directors, and serve as President of Troika. Tom Marianacci, Founder and Chief Executive Officer of Converge will remain CEO of the Converge entities and be a board advisor to Troika. Other members of Converge's Executive Leadership Team have agreed to join Troika to provide continuity to Troika's strategy, growth and leadership. Provides Significant Revenue and Earnings Growth Opportunity. Converge generated approximately $300 million of revenues and adjusted EBITDA of $23 million for the year ended December 31, 2021. Generates Strong Cash Flow to Support Balanced Capital Allocation Plans. Estimated Combined Adjusted EBITDA over $27 Million for CY 2022. Accretive to adjusted earnings per share.

07:58 EST Wayfair: Path ahead 'sure to be everything but a straight line' - In its quarterly shareholder letter, Wayfair said it has line of sight on an "ambitious but measured plan to reach a double-digit market share and grow to be a $100 billion+ revenue company."

07:56 EST U.S. Energy reports 2021 SEC total estimated proved reserves of 1.3 MMBoe - U.S. Energy Corp announced its year-end 2021 SEC total estimated proved reserves of approximately 1.3 MMBoe and $20.6 million of PV-10. Incorporating the Company's recently announced acquisitions which closed on January 5, 2022 and utilizing NYMEX strip pricing, total proved reserves as of year-end were 6.0 MMBoe and $109.8 million of PV-10. "2021 was a transformational year for U.S. Energy and has positioned the Company to continue executing its strategy of opportunistic growth and financial discipline," said Ryan Smith, Chief Executive Officer of U.S. Energy, who continued, "With the closing of our Acquisitions at the beginning of the year, we have expanded our operations into geographically diverse assets that generate significant cash flow, allowing us to remain focused on our consolidation initiatives. As we move into 2022, we continue forward on building a diversified business of scale that produces substantial free cash flow and drives capital returns for U.S. Energy shareholders."

07:54 EST Bombardier says 2025 objectives 'on track' - Bombardier will host a virtual 2022 Investor Day this morning to provide an update on the execution of its 2025 financial targets outlined a year ago. The company's leadership will review Bombardier's strong performance in 2021 and provide an in-depth look at the execution of its strategic plan and the outlook through 2025. Eric Martel, President and Chief Executive Officer, will be joined by Bart Demosky, Executive Vice President and Chief Financial Officer and Jean-Christophe Gallagher, Executive Vice President, Services and Support, and Corporate Strategy in outlining the progress made on the four key pillars of Bombardier's 2025 plan and provide an update on the steps ahead. In the coming years, the company will prioritize debt reduction to continue deleveraging the business and build a more resilient company. On the back of a strong foundation forged in 2021, Bombardier was already able to launch repayment of an incremental $400 million of debt, utilizing cash from the balance sheet, and will continue to be opportunistic in its deleveraging strategy, targeting a minimum of 24 months maturity runway and continuing to work to optimize liquidity. With a fleet of approximately 5,000 aircraft globally, Bombardier is steadily growing its share of the lucrative aftermarket business. The aftermarket team delivered a 25% jump in revenues year over year in 2021. In Q4 2021, the business's revenues reached $363 million, 44% higher than Q4 2020 and 17% higher than in Q4 2019. With business aviation flight hours recovering to surpass pre-pandemic levels and a number of facility expansions under way or reaching completion, aftermarket revenues are expected to continue to grow at a double-digit CAGR, putting the company well on track to reach the goal of $2 billion in aftermarket revenues by 2025. Jean-Christophe Gallagher will provide an overview and data on the decisions the company has made so far to grow the segment, as well as its strong plan for the coming years. With the imminent delivery of the 100th Global 7500 aircraft, the industry flagship continues to redefine the business aviation landscape with significant market acceptance, particularly among fleet operators. In 2021, the program was a positive adjusted EBITDA contributor. The company will outline the continued positive outlook for this program ahead, with expectations to more than double its adjusted EBITDA contribution between 2021 and 2025. Overall in 2021, the company reached $135 million in cost savings, surpassing its objective by $35 million and bringing it firmly on track towards its 2023 objective of $400 million in recurring savings. Bart Demosky will further outline the current financial performance of the company, its strategy to meaningfully grow earnings over the next years, in line with targets, and the company's flexible path forward in terms of strategic capital allocation Bombardier 2025 Objectives Tracking to Plan. Total Revenues ~$7.5 billion; Adjusted EBITDA1~$1.5 billion; Adjusted EBITDA margin3~20%; Free-cash-flow1 greater than$500 million; Adjusted net debt to adjusted EBITDA ratio~3x

07:52 EST Arrowhead completes enrollment of Phase 2b ARCHES-2 study of ARO-ANG3 - Arrowhead Pharmaceuticals announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the company's investigational RNA interference therapeutic being developed as a treatment for patients with mixed dyslipidemia. Completion of ARCHES-2 is anticipated around the end 2022 and the company intends to release topline data in the first half of 2023. Javier San Martin, M.D., chief medical officer at Arrowhead, said: "Arrowhead's investigational ARO-ANG3 is designed to silence the hepatic expression of angiopoietin-like protein 3 , a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum and liver triglycerides, serum LDL cholesterol, and has genetic validation as a novel target for cardiovascular disease. The ARCHES-2 clinical study will evaluate safety and efficacy and identify an optimal dose and dosing regimen of ARO-ANG3 to be assessed in future late-stage clinical studies. I want to thank the participating investigators and our entire clinical team for their hard work to enroll this study rapidly and effectively. We look forward to sharing topline data for ARCHES-2 in the first half of 2023."

07:50 EST Chimerix presents preclinical data on CMX521 program - Chimerix in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel Hill announced that preclinical data from the Company's CMX521 program will be featured in a late-breaking oral presentation session at the International Conference on Antiviral Research on Wednesday, March 23, 2022 from 12:15 - 1:00 pm PT. "The presentation is titled, "The nucleoside analog antiviral CMX521 inhibits SARS-CoV-2 in human airway epithelial cell cultures and exhibits prophylactic and therapeutic efficacy against respiratory disease in a mouse model of SARS-CoV-2 infection", highlights in vitro activity and in vivo efficacy of this novel compound. In vitro, CMX521 was shown to inhibit SARS-CoV-2 replication in primary human airway epithelial cells with an average EC50 of 0.9microM. In vivo, studies were performed in an animal model used during development of a different antiviral therapy which has obtained Emergency Use Authorization for SARS-CoV-2 in the United States. The animal studies randomized mice to CMX521 or placebo at various times relative to viral infection to explore the potential for prophylactic and therapeutic efficacy. Monotherapy prophylactic administration of aerosol CMX521 every eight hours starting eight hours prior to infection reduced average viral titers in lung on day four post-infection by 3.62 log10 and prevented weight loss/clinical progression versus placebo. Antiviral efficacy was also demonstrated with monotherapy treatment when CMX521 was initiated post-infection. CMX521 treatment significantly reduced SARS-CoV-2 in the lung and protected mice from clinical symptoms of disease including weight loss and adverse lung pathology at day four post-infection relative to placebo. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. In addition, oral CMX521 demonstrated a favorable profile in GLP toxicology studies and was well-tolerated up to 2,400 mg in a healthy volunteer Phase 1 study for a different indication.

07:49 EST BioCryst presents new data from APeX-2 clinical trial of ORLADEYO - BioCryst Pharmaceuticals announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO. The data are being presented at the 2022 American Academy of Allergy, Asthma & Immunology annual meeting, which is being held live in Phoenix, Arizona, and virtually, from February 25-28, 2022. APeX-2 included 121 HAE patients who were randomized 1:1:1 to ORLADEYO 110 mg or 150 mg, or placebo, once daily for 24 weeks. At Week 24, patients on ORLADEYO continued on the same dose and placebo patients were re-randomized to ORLADEYO 110 mg or 150 mg for another 24 weeks. At Week 48 and thereafter, all patients continued on ORLADEYO 150 mg. The 96-week safety and efficacy data were previously reported in July 2021. These additional analyses from APeX-2, as reported in the posters at AAAAI, evaluated the long-term efficacy of ORLADEYO 150 mg in patients who completed 96 weeks of treatment. In APeX-2, ORLADEYO was safe and generally well tolerated, with no drug-related serious adverse events reported. Sustained Reductions in Hereditary Angioedema Attack Rates Observed over 96 Weeks of Oral Berotralstat Treatment Regardless of Initial Response This analysis stratified all 21 patients by their initial reduction in HAE attack rate from baseline to Week 24 in three groups: Group A, Group B and Group C. To note, Group C was a subset of Group B. A sustained reduction in HAE attack rates was observed from baseline to Week 96 across all three groups of patients. Group A had a mean decrease of 2.3 attacks/month, Group B had a mean decrease of 2.5 attacks/month and Group C had a mean decrease of 2.6 attacks/month. The percentage of attack-free days across all patients for the entire study duration was 94 percent, demonstrating ORLADEYO is an effective oral HAE prophylactic treatment even in patients who may have a lower initial response. Oral Berotralstat Treatment for 96 Weeks Consistently Reduces Hereditary Angioedema (HAE) Attack Rates Regardless of Baseline Attack Rate This analysis stratified all 21 patients based on baseline attack rate: Group 1, Group 2 and Group 3. A greater than80 percent reduction in mean attack rates was observed at Week 96 of treatment regardless of the patients' baseline attack rates. At Week 96, median attack rates were 0.0 regardless of baseline attack rate. These data demonstrate ORLADEYO is an effective prophylactic therapy for patients with HAE regardless of baseline attack rate. Sustained Improvement Observed in Patient-Reported Quality of Life with 96 Weeks of Oral Berotralstat Treatment This analysis assessed the QoL of all 21 patients using the Angioedema Quality of Life Questionnaire, a validated tool to measure QoL impairment in patients with recurrent angioedema. The minimal clinically important difference was defined as a change of six points in total score. A mean of 77 percent of patients reported clinically meaningful improvements using the AE-QoL total scores, including improvements observed as early as Week 4, and at each time point through 96 weeks of treatment. The largest improvement was observed in the functioning domain with a mean improvement of 33.4 points at Week 96, suggesting patients reported less impairment in their day-to-day activities while on ORLADEYO 150 mg. The improvement in total AE-QoL scores and the percentage with an MCID in these long-term results show that patients continue to experience QoL improvements compared to baseline over time with ORLADEYO. All posters are available to meeting registrants and will be on display in the poster hall in the Phoenix Convention Center during the meeting.

07:48 EST Marcus announces CFO Neis will retire May 15, Chad Paris to suceed - The Marcus Corporation announced that executive vice president and chief financial officer Douglas A. Neis will retire May 15, after 36 years of service. As part of this planned transition, Chad Paris, current corporate controller and treasurer of The Marcus Corporation, will be promoted to chief financial officer upon Neis's retirement. Neis will serve as an advisor to the company following the transition. "Doug has been a friend and valued colleague since the day I joined The Marcus Corporation, and I know I speak for all of us when I say how grateful we are for the impact he has made on our company," said Gregory S. Marcus, president and chief executive officer of The Marcus Corporation. "Over the course of 36 years, Doug has been a stalwart through times of growth and opportunity as well as times of change and challenge. Yet through it all, Doug kept us on course thanks to his thoughtful foresight, unbending integrity, and calm 'get it done' demeanor. This is true even in how he approached his retirement, with smart planning and deft execution in recruiting, mentoring, and soon promoting Chad Paris as his successor. Since joining the company in October 2021, Chad has worked closely with Doug and me to understand our financial structure and our focus on maintaining a strong balance sheet, which has served us well over the years. Quite quickly Chad became a natural part of our team, and I am thrilled a professional of his caliber and character will support our strategy in the years ahead."

07:45 EST Clene presents data from two Phase 2 MS trials - Clene announced the presentation of updated blinded interim data from its VISIONARY-MS study and results from its REPAIR-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022, taking place Feb. 24-26, 2022, in West Palm Beach, Fla. These data further support Clene's lead drug candidate, CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for Multiple Sclerosis. The first poster, titled "VISIONARY-MS: Update to a Phase 2 Clinical Trial of CNM-Au8, Catalytically Active Gold Nanocrystal Suspension, for the Treatment of Chronic Optic Neuropathy," includes updated blinded data from the ongoing VISIONARY-MS Phase 2 clinical trial evaluating the efficacy and safety of CNM-Au8 as a remyelinating and neuro-reparative treatment in MS patients. In this Phase 2 study, the efficacy and safety of CNM-Au8 versus placebo is being evaluated in stable relapsing MS patients with chronic optic neuropathy who are currently receiving disease-modifying therapy. Blinded analyses presented compared changes in the overall study population's modified Multiple Sclerosis Functional Composite values over the 48-week treatment period to the baseline values of study participants with mild disease as defined by pre-treatment Expanded Disability Status Scale scores of 1.5 or less. Changes in the four mod-MSFC domains mean standardized change showed increasing improvements for LCLA; averaged MSFC scores; and individual MSFC domains, including SDMT (pless than0.0001 vs. baseline), 9HPT dominant-hand, and 9HPT non-dominant hand (pless than0.002). These data support CNM-Au8's potential to drive meaningful neurological improvements in stable relapsing MS patients. The second poster, titled "Improvement of Brain Energy Metabolism in Relapsing Multiple Sclerosis Patients: Results from Phase 2 REPAIR-MS Clinical Trial With CNM-Au8," demonstrated that utilizing high-resolution magnetic resonance spectroscopy in stable relapsing MS patients, CNM-Au8 showed CNS target engagement resulting in improved brain energetic metabolism. In the pre-specified integrated analysis across two identical clinical trials, the results for the primary endpoint, mean change in brain NAD+/NADH ratio, demonstrated a statistically significant increase of 10.4% following 12-weeks of treatment with CNM-Au8, with the REPAIR-MS trial itself demonstrating a 14.3% improvement. REPAIR-MS incorporated a third 31P-MRS scan following a six-week treatment washout, which demonstrated a return to baseline in mean NAD+/NADH ratio levels following withdrawal of CNM-Au8. Exploratory endpoints showed that CNM-Au8 administration resulted in normalization of several critical markers of brain energy production capacity, including beta-ATP levels and phosphorylation potential.

07:42 EST Macellum issues statement to Kohl's following nomination of director nominees - Macellum Advisors, a long-term holder of nearly 5% of the outstanding common shares of Kohl's issued the following statement after Macellum's nomination of ten independent individuals for election to the board of directors at the 2022 annual meeting of shareholders: "The Company hastily rejected recent indications of interest and has refused to announce a robust strategic review process. The Board's rejections came just two weeks after outreach from potential acquirers, reaffirming our belief that a majority of the Board is entrenched and lacks the objectivity necessary to evaluate potentially value-maximizing sale opportunities. Furthermore, it appears the Board has still not authorized its bankers to aggressively canvass the market and initiate substantive conversations with a broader set of logical suitors. We are forced to question the Board's commitment to running an open, fair and fulsome process and providing adequate information to potential buyers to increase prospective offer prices. The Board recently adopted a two-tiered poison pill, which seems like it was deliberately structured to chill a sale process. The pill prevents a potential acquirer from bringing an offer directly to shareholders without risking substantial dilution. In fact, simply announcing an intent to commence a tender offer (as opposed to consummating one) triggers the pill. While the Board may point to the 'qualified offer' exception, the various requirements that must be met to be a 'qualified offer' all but ensure that no unsolicited offer will ever be made. The requirements include that an offer must be fully financed, not subject to any diligence and not arbitrarily deemed 'inadequate' by the Company's investment bank. Unsurprisingly, despite our concerns, the Board has yet to commit to submitting this onerous, two-tiered pill for shareholder approval at the upcoming Annual Meeting. The Board has yet to address our good faith request for a universal proxy card to be used at the Annual Meeting. Given that the Board claims to be a leader when it comes to environmental, social and governance matters, we assumed it would want to be a voluntary early adopter of the U.S. Securities and Exchange Commission's new rule for universal cards in contested elections that is scheduled to go into effect in September of 2022. The Board's lack of response to our request to have all candidates appear on both Macellum and the Company's proxy cards is troubling. The Board appears to have pushed up this year's record date by three weeks to March 7, 2022, in an apparent attempt to protect itself from investors who are rightfully frustrated by its inaction and poor direction.1 Given that the Company is set to report earnings on March 1st, shareholders do not have reasonable time to add to their positions with all the facts in front of them if they want to have a say at the upcoming Annual Meeting. Further, the record date would require a shareholder to have purchased shares prior to the long-awaited analyst day scheduled to take place on March 7th."

07:39 EST Morphic sees cash runway until end of 2024 - As of December 31, 2021, Morphic had cash, cash equivalents and marketable securities of $408.1 million, compared to $228.3 million as of December 31, 2020. In the full year and fourth quarter 2021, Morphic raised net proceeds of $25.7 million and $1.1 million from the use of our At-The Market (ATM) facility. To date in 2022, Morphic has not issued any stock through its ATM facility. Morphic believes its cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to fund operating expenses and capital expenditure requirements until the end of 2024.

07:38 EST Protalix, Chiesi Global submit MAA to EMA for PRX-102 - Protalix BioTherapeutics and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., announced the submission of a Marketing Authorization Application via centralized procedure to the European Medicines Agency for pegunigalsidase alfa (PRX-102) for the proposed treatment of adults with Fabry disease, and the subsequent validation of the MAA by the EMA.

07:36 EST Cars.com announces $200M share repurchase program - Cars.com has authorized the repurchase of up to $200M of the company's outstanding shares of common stock over the next three years. The company intends to fund the share repurchase program with cash from operations.

07:31 EST Pluristem announces closing of collaboration with Tnuva Group - Pluristem Therapeutics and Israel's largest food producer Tnuva Group announced today the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry. The collaboration is a major step forward to bringing sustainable cultured food to everyday consumers globally. The closing of the deal marks the incorporation of a new company that will receive exclusive, global, royalty bearing licensing rights to use Pluristem's proprietary technology, intellectual property, and knowhow, to be used in the field of cultured meat products of all kinds. Tnuva invested $7.5 million in NewCo, according to a pre-money valuation of $40 million, and currently owns approximately 16% of NewCo, while Pluristem owns approximately 84% of NewCo's outstanding shares. Tnuva has an option to invest up to an additional $7.5 million over the next 12 months. The announcement of NewCo's CEO is planned for March 2022.

07:29 EST Ruth's Hospitality sees FY22 CapEx $53M-$58M

07:27 EST Renalytix announces presentation of data for KidneyIntelX testing - Renalytix announced the presentation of new clinical data for KidneyIntelX bioprognostic testing at the World Congress of Nephrology Annual Meeting. The results provide robust prognostic information demonstrating the value of KidneyIntelX to predict the future rate of decline in kidney function compared with current standard diagnostics in patients with early-stage chronic kidney disease and type 2 diabetes, including estimated glomerular filtration rate, urine albumin-creatinine ratio, and eGFR slope. Advanced risk assessment tools, such as KidneyIntelX, enable primary care physicians to make optimized treatment decisions through accurate determination of individual patient risk and provide the opportunity to change intensity of care management based on that risk. In the short term, KidneyIntelX can more efficiently assess the integrated impact of changes in key risk factors on overall kidney health, which often do not manifest in kidney function improvements for several years. KidneyIntelX is the only early-stage, bioprognostic solution for kidney health, and has received Breakthrough Device Designation from the U.S. Food and Drug Administration. Highlights from the abstracts are as follows: Abstract WCN22-0561: "Added Value of KidneyIntelX for Predicting Future Kidney Function Decline Compared with Historical eGFR Trajectories" Traditional kidney metrics, such as high albuminuria or low estimated eGFR, or historical rate of eGFR decline, do not adequately determine "future progression" of kidney disease The independent prognostic value of KidneyIntelX was assessed for future outcomes above and beyond traditional kidney metrics The KidneyIntelX risk score provided robust prognostic information for future eGFR trajectories and adverse kidney outcomes beyond ascertainment of baseline kidney function, glomerular injury, or historical kidney function trajectories This shows additional utility of KidneyIntelX for clinical care risk stratification and enrichment for clinical trials beyond commonly used measures Abstract WCN22-0564: "Association of Changes in Modifiable Factors with Changes in KidneyIntelX Risk Scores in the CANVAS Participants with Prevalent Diabetic Kidney Disease" Prior analyses from the CANVAS trial cohort have shown that changes in a patient's KidneyIntelX score over time were informative of prognosis above and beyond the baseline KidneyIntelX score The associations between changes in common clinical treatment targets such as systolic blood pressure, HbA1c, and UACR with early improvements in kidney health, as measured by KidneyIntelX, were not previously explored Longitudinal improvements to target SBP, HbA1c and UACR resulted in meaningful and robust changes in the KidneyIntelX risk score, particularly in individuals randomized to canagliflozin, in this post hoc analysis In sum, these data suggest that KidneyIntelX can be used in conjunction with clinical features to reinforce the beneficial effects accrued from the treatments in patients with DKD

07:23 EST Aerie Pharmaceuticals names Gary Sternberg as Chief Medical Officer - Aerie Pharmaceuticals announced that Gary Sternberg, M.D., M.B.A., will join the company as Chief Medical Officer, effective March 1. He will report to Raj Kannan, CEO of Aerie Pharmaceuticals and become a member of the Aerie Executive Committee. Gary joins Aerie from RainBio where he served as Acting CEO.

07:22 EST C4 Therapeutics expects cash to fund planned operating expenses to end of 2024 - Cash, cash equivalents and marketable securities as of December 31, 2021 were $451.5 million, compared to $371.7 million as of December 31, 2020. The change in cash was primarily driven by net proceeds from our June 2021 follow-on public offering of $169.5 million, offset by expenditures to fund operations. C4T expects that its cash, cash equivalents and marketable securities as of December 31, 2021, together with future payments expected to be received under existing collaboration agreements, will be sufficient to fund planned operating expenses and capital expenditures to the end of 2024.

07:21 EST Cogent increases quarterly dividend 3% to 85.5c per share - Cogent's board approved a regular quarterly dividend of 85.5c per common share payable on March 25 to shareholders of record on March 9. This Q1 regular dividend represents a 3% increase from Q4 dividend of 83c per share and an annual increase of 13.2% from the Q1 2021 dividend of 75.5c per share.

07:20 EST Kymera Therapeutics expects cash to fund operational plans into 2025 - As of December 31, 2021, Kymera had approximately $567.6 million in cash, cash equivalents, and investments. Kymera expects that its cash, cash equivalents, and investments as of December 31, 2021, excluding any future potential milestones from collaborations, will enable the Company to fund its operational plans into 2025 while the Company continues to identify opportunities to accelerate growth and expand its pipeline, technologies, and clinical indications.

07:18 EST DigitalOcean announces stock repurchase up to an aggregate of $300M - DigitalOcean announced that its board of directors has approved the repurchase of up to an aggregate of $300 million of its common stock to offset expected dilution from employee share grants over the next few years and the opportunistic repurchase of other shares. The repurchases will be made from time to time in the open market at prevailing market prices or in negotiated transactions off the market. "This stock buyback is a commitment to our investors that we will take advantage of our positive free cash flow and strong balance sheet to offset dilution that we will experience from equity grants made to attract and retain employee talent and maximize stockholder value," said Yancey Spruill.

07:17 EST Ramaco Resources to acquire Ramaco Coal - Ramaco Resources announced that it has reached an agreement in principle for its subsidiary, Ramaco Development, LLC, to acquire 100% of the equity interests of Ramaco Coal, an entity owned by an investment fund managed by Yorktown Partners, LLC and certain members of the company's management. The consideration for the Acquisition will consist of (i) an initial payment of $5M due at closing and (ii) an aggregate deferred purchase price of $60M, consisting of (A) $20M, to be paid during the remainder of 2022 in $5M ratable quarterly installments, and (B) $40M, to be paid during 2023 in $10M ratable quarterly installments. The Special Committee of Independent Directors of the Board of Directors of the Company negotiated and approved the Acquisition, which remains subject to customary closing conditions, including obtaining certain consents, and the Company can provide no assurances if or when the closing conditions will be satisfied or whether the Acquisition will be consummated at all. Janney Montgomery Scott has served as financial advisor to the Special Committee and has provided an independent Fairness Opinion with regard to the transaction.

07:14 EST Novocure expects to achieve 2%-5% active patient growth in 2022 - The company expects to achieve active patient growth between 2% to 5% in 2022, in-line with the growth rate experienced in the fourth quarter of 2021. Longer term, the company continues to expect further adoption in its core GBM business.

07:10 EST Newmont sees FY22 gold production 6.2M ounces - Sees FY22 adjusted tax rate 30%-34%.

07:08 EST ProQR Therapeutics sees cash runway into mid-to-late 2024 - At December 31, 2021, ProQR held cash and cash equivalents of EUR 187.5 million, compared to EUR 75.8 million at December 31, 2020. Net cash used or gained in operating activities during the three month period and full year ended December 31, 2021 was EUR 3.8 million gained and EUR 26.0 million used respectively, compared to EUR 11.8 million used and EUR 47.1 million used for the same period last year.

07:05 EST Agios Pharmaceuticals announces key upcoming milestones - Agios expects to execute on the following key milestones and priorities in 2022: Pyruvate Kinase Deficiency: Receive European Medicines Agency regulatory decision for PYRUKYND in adults with PK deficiency by year-end. Initiate Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies of PYRUKYND in not regularly transfused and regularly transfused pediatric patients with PK deficiency, respectively, in mid-2022. Thalassemia: Enroll a meaningful portion of patients in the Phase 3 ENERGIZE and ENERGIZE-T studies of PYRUKYND in not regularly transfused and regularly transfused adults with thalassemia, respectively, by year-end. Sickle Cell Disease: Complete enrollment in the Phase 2 portion of the RISE UP study of PYRUKYND in sickle cell disease by year-end. Initiate the sickle cell disease cohort of the Phase 1 study of novel PK activator AG-946 in the first half of 2022. Expansion and Acceleration of PK Activation Portfolio: Initiate Phase 2a study of AG-946 in adults with low- to intermediate-risk myelodysplastic syndrome by year-end.Continue to publish clinical and translational data supporting the utility of PK activators across key disease areas and elucidating the burden of disease for PK deficiency, thalassemia and sickle cell disease.

07:04 EST Agios expects cash to enable operating plan through major catalysts - Cash, cash equivalents and marketable securities as of Dec. 31, 2021, were $1.3 billion compared to $670.5 million as of Dec. 31, 2020. The company expects that its cash, cash equivalents and marketable securities will enable the company to execute its operating plan through major catalysts and to cash-flow positivity without the need to raise additional equity.

06:55 EST NN, Inc. to close manufacturing facility in Taunton, Massachusetts - NN, Inc. announced that it will close its manufacturing facility in Taunton, Massachusetts. The decision to close this facility, which is part of NN's Power Solutions group, was made to optimize the company's Aerospace, Defense and Medical manufacturing footprint and as part of its ongoing efforts to improve profitability and cash flow generation. When NN's Taunton facility opened, NN consolidated its Hingham and Franklin operations into Taunton and closed those facilities. The intent of the combined facility was to integrate acquired businesses that would grow NN's Aerospace and Defense business and improve overall capacity utilization. As a result of NN's evaluation of strategic alternatives and de-leveraging initiative, culminating with the sale of its Life Sciences business in October 2020, the Taunton facility has been under-utilized. NN's strategic focus has shifted and is now primarily centered around organic growth opportunities in the rapidly growing electric vehicle and electric infrastructure end-markets. "Consistent with our ongoing continuous improvement initiatives to improve our overall cost structure through various methods including facility rationalization, NN thoroughly evaluated several alternatives to address the under-utilization of the Taunton facility and the resulting impact on our profitability and free cash flow. After careful deliberation, we have concluded that this plan represents the quickest and lowest risk option to achieve our long-term strategic objectives and expect to complete the closure by the end of 2022." said Warren Veltman, President and CEO of NN. Mike Felcher, NN Senior Vice President and CFO, commented, "We remain committed to improving NN's profitability and driving strong free cash flow generation while maintaining sufficient liquidity and flexibility in our capital structure to invest in key strategic growth areas. Through the first nine months of 2021, the under-utilization of the Taunton facility resulted in an operating loss of $4.7 million which included $1.0 million of depreciation. We believe that rationalizing our AD&M manufacturing footprint will improve our long-term financial results and better position NN to achieve its strategic growth objectives." The closure of the Taunton facility will involve relocating customers that meet volume and profitability requirements to other NN facilities. NN expects to incur costs in the range of $1M-$1.5M for employee severance and equipment relocation. In addition, the company expects to sublease the facility upon exit which may result in additional costs. The closure of the plant will affect approximately 85 salaried and hourly employees. In instances where employees are not offered employment at another NN manufacturing facility, support will be provided in terms of transition and employee assistance.

06:40 EST EU commercial vehicle registrations down 11.1% in January - In January, new commercial vehicle registrations in the European Union declined by 11.1% to 125,292 units. This drop was mainly the result of a fall in new van sales, reported the European Automobile Manufacturers Association. Three of the four key markets in the region posted a decline last month. Spain saw the sharpest drop, followed by France and Germany, the group said. Publicly traded truck makers and suppliers include Daimler AG (DDAIF), Paccar (PCAR), CNH Industrial (CNHI), Navistar (NAV), Cummins (CMI) and Allison Transmission (ALSN).

06:29 EST AB InBev sees FY22 EBITDA in line with 4%-8% medium-term outlook - The company said: "We expect our EBITDA to grow in-line with our medium term outlook of between 4-8% and our revenue to grow ahead of EBITDA from a healthy combination of volume and price. The outlook for FY22 reflects our current assessment of the scale and magnitude of the COVID-19 pandemic, which is subject to change as we continue to monitor ongoing developments. We expect the normalized ETR in FY22 to be in the range of 28% to 30%, excluding any gains and losses relating to the hedging of our share-based payment programs. The ETR outlook does not consider the impact of potential future changes in legislation. We expect net capital expenditure of between $4.5B-$5B in FY22."

06:20 EST Six Flags reports Q4 attendance 98% vs. 4Q19 - In the fourth quarter, attendance at the company's parks was approximately 98% compared to the comparable fiscal period in 2019. Attendance by pre-booked groups, inclusive of school groups who typically book in advance, has been significantly diminished due to the pandemic. Excluding pre-booked groups, attendance at the company's parks in fourth quarter 2021 was approximately 100% compared to the same period in 2019.

06:16 EST Denbury enters strategic alliance with Infinium - Infinium announced that the company has entered into a strategic alliance with Denbury to collaborate on developing ultra-low carbon fuels projects in the state of Texas. Infinium electrofuels facilities being developed in Brazoria County will convert renewable power into green hydrogen and combine it with industrial-sourced carbon dioxide, or CO2, to produce ultra-low carbon fuels using Infinium proprietary technology. Under the strategic alliance, Denbury will source and transport CO2 to the Infinium facilities, which are planned to be sited near Denbury's existing and planned CO2 pipeline infrastructure. Denbury estimates that the pipeline infrastructure necessary to deliver CO2 to the Infinium facilities will be ready as early as 2025. The facilities are anticipated to utilize 1.5M tons of CO2 per year that would otherwise be emitted into the atmosphere.

06:13 EST Grifols announces AT-III collaboration with Endpoint Health - Grifols announced a collaboration with Endpoint Health, a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III, or AT-III, therapy to treat Sepsis. As part of the agreement, Grifols will contribute its expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients with blood clotting issues. As part of the collaboration, and subject to the FDA's acceptance of its IND and Investigational Device Exemption, or IDE, filings, Endpoint Health will deploy its AI technology and its proprietary diagnostic test in a phase II trial designed to identify septic patients mostly likely to respond to AT-III. Upon FDA approval, the companies will invest in a build-out of AT-III production at Grifols sites.

06:07 EST Ford recalls 330,000 2015-2017 Ford Mustangs to fix rearview camera - Ford Motor Company is recalling about 330,000 model year 2015-2017 Ford Mustangs due to concerns that the backup camera wiring may be loose or damaged, leading to a blank or distorted image when reversing. If that happens, drivers may not be able to see people or obstacles behind them, which could lead to a crash, according to a notice posted on the NHTSA's website. Ford is aware of two reports of minor crashes and no reports of injury related to this condition.

05:44 EST Teck Resources announces C$100M share repurchase program - Teck Resources announced the board has granted management the authority to purchase up to C$100M of Class B subordinate voting shares annually. Additional buybacks will be considered regularly. Taking into account the new annual base dividend in 2022, the supplemental dividend, and assuming the C$100 million in share repurchases, these initiatives represent approximately $635M in aggregate of dividends and potential share repurchases.

05:41 EST Agnico Eagle CEO Anthony Makuch steps down, Ammar Al-Joundi to succeed - Ammar Al-Joundi has been appointed president and CEO, effective immediately. Al-Joundi is an executive with a long history of mining industry experience who previously served as president of Agnico Eagle. With this appointment, Al-Joundi joins the company's board of directors. Anthony Makuch advised the board that he has decided to step down as CEO and as a director of Agnico Eagle.

05:18 EST OneConnect announces share repurchase plan for up to 2% of shares - OneConnect Financial announced its board of directors has approved a share repurchase program in which the company may purchase its own American depositary shares, or ADSs, with an aggregate amount of up to 2% of the total outstanding ordinary shares from February 24 to September 30 pursuant and subject to applicable laws and the company's securities trading policy. OneConnect expects to fund the repurchase from its existing cash balance.